Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases.The Company’s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex’s product pipeline is principally focused on viral diseases, inflammation, autoimmune diseases and cancer. The Company is leading the development of the HCV protease inhibitor, VX-950, and in 2006 is conducting a broad Phase II clinical program of this drug candidate. Vertex is also conducting Phase II clinical development with the p38 MAP kinase inhibitor VX-702. Through collaborations with major pharmaceutical companies, Vertex is developing potentially breakthrough treatments for cancer, HIV and pain. The Company has significant collaborations with Cystic Fibrosis Foundation Therapeutics, Inc., GlaxoSmithKline, Kissei Pharmaceutical Co., Ltd., Merck & Co., Inc., Mitsubishi Pharma Corporation and Novartis Pharma AG. Vertex co-promotes the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.